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Cannabidiol (CBD) has been traditionally used in Cannabis-based preparation, however
historically, it has received far less interest as a single drug than the other
components of Cannabis. Currently, CBD generates considerable interest due to its
beneficial neuroprotective, antiepileptic, anxiolytic, antipsychotic, and anti-inflammatory
properties. Therefore, the CBD scaffold becomes of increasing interest for medicinal
chemists. This review provides an overview of the chemical structure of natural
and synthetic CBD derivatives including the molecular targets associated with these
compounds. A clear identification of their biological targets has been shown to be still
very challenging.
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INTRODUCTION
In the mid-seventies, major efforts were focused on the identification of new natural cannabinoids
isolated from preparations of Cannabis sativa and of other subspecies and varieties, such as
Cannabis indica and Cannabis ruderalis. The two most abundant and most therapeutically relevant
components of the plants are (–)-trans-19–tetrahydrocannabinol (19–THC) and (−)-cannabidiol
(CBD) (Figure 1). Over these last two decades, the endocannabinoid system (ECS) related
to the effects of Cannabis sativa has being emerging as target of pharmacotherapy showing
very considerable physiological significance (Mechoulam et al., 2014). This system includes two
cannabinoid receptors (CB1 and CB2) and endogenous ligands named endocannabinoids (Matsuda
et al., 1990; Munro et al., 1993). CB1 receptor is abundant in the brain, but to a less extend in
peripheral tissues. CB2 receptor is mainly expressed in immune cells.
19–THC is responsible for the psychoactive effects of Cannabis sativa mediated by the
activation of CB1 receptor in the brain, whereas CBD is considered non-psychotropic. Currently,
CBD is clinically used in association with 19–THC in a cannabis-based preparation (Sativex R©)
that contains equimolar content of both for managing neuropathic symptoms associated with
multiple sclerosis (Fernandez, 2016). CBD as a single drug is currently generating considerable
interest due to its beneficial neuroprotective (Fernandez-Ruiz et al., 2013; Scuderi et al., 2014;
Ibeas Bih et al., 2015), antiepileptic (Devinsky et al., 2015; Wright et al., 2015), hypoxia-ischemia
(Lafuente et al., 2011; Mori et al., 2017), anxiolytic (Massi et al., 2013; Schier et al., 2014),
antipsychotic (Bhattacharyya et al., 2010), analgesic (Maione et al., 2011), anti-inflammatory
(Ruiz-Valdepeñas et al., 2011; Burstein, 2015), anti-asthmatic (Ribeiro et al., 2015; Vuolo et al.,
2015), and antitumor properties (McAllister et al., 2011; Massi et al., 2013) among others
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FIGURE 1 | Cannabidiol (CBD) and (–)-trans-19–tetrahydrocannabinol (19–THC).
(Mechoulam et al., 2007; Zhornitsky and Potvin, 2012; Renard
et al., 2017; Watt and Karl, 2017). In 2016, GW pharmaceuticals
reported the first positive results of CBD (Epidiolex R©) in
phase III clinical trials for treatment-resistant seizure disorders,
including Lennox–Gastaut and Dravet syndromes. An overview
of regulatory approvals and clinical trials of CBD has been
recently published (Fasinu et al., 2016).
The molecular targets involved in the diverse therapeutic
properties produced by CBD are still not very well-understood
(Morales et al., 2017). Unlike 19–THC, CBD does not bind to
the orthosteric binding site of the CB1 and CB2 cannabinoid
receptors (McPartland et al., 2007). Despite this lack of
orthosteric affinity, CBD has been shown to antagonize the
effects of the CB1/CB2 agonists CP–55,940 and WIN55212 at
the mouse CB1 and at the human CB2 receptors (Pertwee
et al., 2002; Thomas et al., 2007). Therefore, allosteric activity
of CBD at these receptors has been hypothesized. In a recent
report, CBD was shown to be a negative allosteric modulator
of 19–THC and the endogenous cannabinoid 2–AG providing
a possible explanation for some in vivo CBD effects (Laprairie
et al., 2015; Morales et al., 2016). CBD has also been shown to
modulate endocannabinoid tone by inhibiting the cellular uptake
of the endocannabinoid anandamide (Leweke et al., 2012). This
effect has been attributed to the fact that CBD competes with
anandamide for binding to fatty acid-binding proteins (FABPs)
which are intracellular proteins involved in the transport of
anandamide to its metabolic enzyme fatty acid amide hydrolase
(FAAH) (Elmes et al., 2015). Other possible molecular targets of
CBD have been explored. Modulation of the GPR55 receptor by
CBD has been evaluated in different signaling pathway assays.
CBD acts as an antagonist preventing [35S]GTPγS binding and
Rho activation (Ryberg et al., 2007; Whyte et al., 2009; Ford et al.,
2010), modulating Ca2+ mobilization (Lauckner et al., 2008)
and β-arrestin recruitment (Yin et al., 2009). CBD has also been
proposed as an antagonist of the GPR18 cannabinoid receptor
(McHugh et al., 2012, 2014). Certain actions of CBD such as
anti-inflammatory and immunosuppressive effects appear to be
partially mediated through the serotonin and adenosine receptors
that are not considered part of the ECS. For instance, CBD
acts as a full 5-HT1A agonist, 5-HT2A weak partial agonist and
a non-competitive 5HT3A antagonist (Russo et al., 2005; Yang
et al., 2010; Rock et al., 2012). The ability of CBD to activate
the A1A adenosine receptor has also been proposed (Gonca and
Darıcı, 2014). Other molecular targets have also been studied,
among them, the PPARγ nuclear receptors (O’Sullivan et al.,
2009; Esposito et al., 2011; Scuderi et al., 2014), glycine receptors
(Ahrens et al., 2009; Xiong et al., 2012), GABAA receptors
(Bakas et al., 2016), and transient receptor potential (TRP)
channels (De Petrocellis et al., 2011, 2012). Studies focused on
the possible epigenetic regulation of skin differentiation genes
by CBD revealed that CBD is a transcriptional repressor that
can control cell proliferation and differentiation through DNA
methylation (Pucci et al., 2013). Despite all of this data, the
mechanistic bases for the effects of CBD remain complex.
Cannabidiol constitutes one of the most important
components of therapeutic interest from Cannabis sativa.
However, unlike the numerous synthesized cannabimimetics
generated to provide a synthetic alternative to THC, CBD
derivatives have only been superficially explored. The purpose
of this review is to provide a structural overlook at natural and
synthetic CBD derivatives. Due to the fact that diverse molecular
targets are involved in the therapeutic properties produced by
CBD, we associated CBD structures to their biological targets.
Thus, this review is intended to be a useful tool especially for
medicinal chemists.
The basic structure of the CBD derivatives described in this
review consists of 5-alkyl resorcinols substituted in position 2
by a propenylcyclohexene. Structural modifications on the alkyl
side-chain, on the propenylcyclohexene, and substitution of the
phenolic hydroxyl groups are concerned. Quinone CBD analogs
are also included in this classification as far as their structures are
closely related to CBD.
NATURAL CANNABIDIOL DERIVATIVES
In a recently published review dedicated to the diversity of
cannabis phytocannabinoids, the authors updated the inventory
of naturally occurring CBD derivatives (Hanuš et al., 2016).
Herein, we are associating these structures to their possible
molecular targets.
Of the over 100 natural cannabinoids identified in Cannabis
Sativa, seven have been classified as CBD-type compounds
including CBD (Figure 2) (ElSohly and Slade, 2005; ElSohly and
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FIGURE 2 | Natural phytocannabinoid CBD analogs.
Gul, 2014; Aizpurua-Olaizola et al., 2016). All of them have the
same absolute configuration than CBD; they are 5′-methyl-2′-
(prop-1-en-2-yl)-1′,2′,3′,4′-tetrahydro-[1,1′-biphenyl]-2,6-dioles
retaining the trans-(1R,6R) configuration. Cannabidiolic
acid (CBDA) and cannabidivarinic acid (CBDVA-C3) are
C3′-carboxylic derivatives, whereas cannabidiorcol (CBD-C1),
cannabidiol-C4 also named as nor-cannabidiol (CBD-C4),
and cannabidivarin (CBDV) differ from CBD by the length
of their C4′-side chain. Cannabidiol monomethyl ether
(CBDM), the C6′-methoxy CBD analog, was also isolated
from the plant. Despite the potential therapeutic interest
of these naturally occurring CBD derivatives, only a few
related pharmacological studies have been reported (Table 1).
Like most non-steroidal anti-inflammatory drugs, CBDA is
characterized by a carboxylic group resulting in a selective
inhibition of cyclooxygenase-2 (Takeda et al., 2008). CBDA
does not have effect on anandamide inactivation in FAAH
assays (Inhibition of [14C]-anandamide uptake: IC50 > 50 µM)
contrary to CBD (IC50 = 28 µM) (Bisogno et al., 2001; Ligresti,
2006). Other molecular targets proposed for CBDA include
GPR55 (Anavi-Goffer et al., 2012) and TRPA1 with moderate
activity (De Petrocellis et al., 2011). CBDA has been shown
to be an inhibitor of cell migration in the highly aggressive
human breast cancer MDA-MB-231 by alteration of Rho
GTPase activity (Takeda et al., 2012). CBDV, the C4′-propyl
analog of CBD, displays very weak affinity for CB1 and CB2
receptors (Hill et al., 2013; Rosenthaler et al., 2014), whereas
it has been reported to inhibit the activity of the putative
endogenous ligand LPI in hGPR55-HEK293 cells (Anavi-
Goffer et al., 2012). CBDV also targets the human TRPA1
channel (De Petrocellis et al., 2011, 2012). In several animal
seizures models, CBDV exerted notable anticonvulsant effects
without affecting normal motor function (Hill et al., 2012). The
mechanisms through which CBDV exerts its antiepileptic effects
are uncertain (Jones and Whalley, 2015). CBDV is currently in
Phase II clinical trials as an antiepileptic drug under the name
GWP42006.1
Two aromatic analogs of CBD have been isolated from
Lebanese hashish (ElSohly and Slade, 2005): cannabinodiol
(CBND-C5), and cannabinodivarin (CBND-C3) (Figure 3)
whose structural elucidation required their total synthesis
(Robert et al., 1977). CBND-C5 found in the plant’s flowers in low
concentration, is considered a product of CBD photochemical
conversion.
The conversion of CBD into human metabolites has been
the subject of a recent interesting review (Ujváry and Hanuš,
2016). CBD biotransformation shows considerable species
variability. The main biotransformation, including hydroxylation
and oxidation, involves the CYP450 enzyme family. While
7-hydroxy-CBD (7-OH-CBD) derivatives are found in low
concentration, the most abundant metabolites are hydroxylated
7-carboxylic acid derivatives of CBD (7-COOH-CBD, Figure 4).
Glucuronidation of CBD seems to frequently occur at the
phenolic oxygen (Figure 4). Another cannabinoid metabolite,
the so called cannabielsoin (CBE), has been identified in
plants as a product of photo-oxidation from CBD and CBDA
(Shani and Mechoulam, 1974; Ujváry and Hanuš, 2016), or by
biotransformation using tissue cultures under normal growth
conditions (Hartsel et al., 1983; Yamamoto et al., 1991). CBE
was also identified as a metabolite in guinea pigs, mice, rabbits,
and rats (Yamamoto et al., 1991). Despite the fact that CBD
1ClinicalTrials.gov. A Study of GWP42006 in People With Focal Seizures. https:
//clinicaltrials.gov/ct2/show/NCT02369471 (accessed September 22, 2016).
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metabolites have been the subject of many studies, few in vivo
studies have been published. Therefore, their therapeutic benefits
remain to be established.
Beyond the Cannabis plant, other naturally occuring products
have been reported to interact with the ECS (Gertsch et al., 2010).
However, only few of them are CBD-based compounds. Isolation
and characterization of (+)-trans-hexahydrodibenzopyrans from
the stem bark of the Amazonian liana Machaerium multiflorum
Spruce led to the identification of the CBD related structures
machaeridiols A, B, and C (Figure 5) (Muhammad et al., 2003).
The total synthesis of these compounds via an efficient highly
regio- and stereoselective approach has also been described
(Huang et al., 2007). Although their activity at the CB1
and CB2 cannabinoid receptors has not been reported, these
compounds displayed antimicrobial, antifungal, and antiparasitic
activity in diverse in vitro assays (Muhammad et al., 2003).
Machaeridiol B stands out as the most potent inhibitor
against Plasmodium falciparum [chloroquine-sensitive (D6) and
chloroquine-resistant (W2) clones] and Leishmania donovani
with IC50 values in the low micromolar range (Table 1).
TABLE 1 | CB1/CB2 cannabinoid receptor binding, molecular targets and therapeutic potential of CBD derivatives.
Compounds CB1R Ki [nM] CB2R Ki [nM] Reference Other targets Therapeutic
potential
Reference
(−)-CBD >10000 >10000 Bisogno et al., 2001 NAM-CB1; FABPs;
GPR55; GPR18;
5-HT1A; 5-HT2A;
5-HT3A; GlyR A1A;
PPARγ; GABAA, TRPs
Neuroprotection;
epilepsy;
anxiety;
psychosis;
inflammation
Fasinu et al., 2016;
Morales et al., 2017
(−)-CBDA COX-2; TRPA1; DAGLα Inflammation;
cancer;
bacteria
Appendino et al.,
2008; Takeda et al.,
2008, 2012; De
Petrocellis et al.,
2011
(−)-CBDV 14711 ± 5734 574.2 ± 146 Rosenthaler et al., 2014 GPR55; TRPA1;
CYP1A1
Convulsion;
epilepsy
De Petrocellis et al.,
2011; Anavi-Goffer
et al., 2012; Hill
et al., 2012, 2013;
Yamaori et al.,
2013; Rosenthaler
et al., 2014; Jones
and Whalley, 2015
Machaeridol B − − − Plasmodium
falciparum;
Leishmania
donovani
Muhammad et al.,
2003
Ferruginene C NR Weak Seephonkai et al., 2011 TRPA1 Cancer Seephonkai et al.,
2011
(−)-7-OH-CBD >10000 >10000 Bisogno et al., 2001 −
(+)-7-OH-CBD 5.3 ± 0.5 101.0 ± 5.1 Fride et al., 2004 − −
(−)-7-COOH-CBD >10000 >10000 Bisogno et al., 2001 − −
(+)-7-COOH-CBD 13.2 ± 0.4 312.8 ± 15.8 Fride et al., 2004 − −
CBE − − CYP1A1 − Yamaori et al., 2013
(+)-CBD 842 ± 36 203 ± 16 Bisogno et al., 2001 − −
H2-CBD >1000 − Ben-Shabat et al., 2006 − Inflammation Ben-Shabat et al.,
2006
H4-CBD 145 − Ben-Shabat et al., 2006 − Inflammation Ben-Shabat et al.,
2006
HU-444 >10000 >10000 Haj et al., 2015 − Inflammation Haj et al., 2015
HU-446 ∼1000 >10000 Kozela et al., 2015 − Inflammation Haj et al., 2015
HU-465 76.7 ± 58 12.1 ± 2.3 Kozela et al., 2015 − Inflammation Haj et al., 2015
(−)-DMH-CBD >10000 >1000 Bisogno et al., 2001 − Anxiety; pain;
inflammation;
cancer
Burstein, 2015;
Juknat et al., 2016
(+)-DMH-CBD 17.4 ± 1.8 211 ± 23 Bisogno et al., 2001 − −
(−)-7-OH-DMH-CBD >4000 671 ± 12 Bisogno et al., 2001 TRPV1, opioid, α2-AR − Fride et al., 2005;
Pertwee et al.,
2005
(Continued)
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TABLE 1 | Continued
Compounds CB1R Ki
[nM]
CB2R Ki
[nM]
Reference Other targets Therapeutic
potential
Reference
(+)-7-OH-DMH-CBD 2.5 ± 0.03 44.0 ± 3.1 Bisogno et al., 2001 − −
(−)-7-COOH-DMH-CBD (HU-320) > 1000 >4000 Bisogno et al., 2001 − Inflammation,
immunosuppression
Sumariwalla et al., 2004
(+)-7-COOH-DMH-CBD 5.8 ± 0.7 155.5± 5.3 Fride et al., 2004 − −
H2-DMH-CBD 124 − Ben-Shabat et al., 2006 −
H4-DMH-CBD 17 − Ben-Shabat et al., 2006 −
HU-308 >10000 22.7 ± 3.9 Hanus et al., 1999 − Inflammation;
hepatic ischemia;
osteoporosis; pain
Ofek et al., 2006;
Rajesh et al., 2007a,b;
Burstein, 2015
(−)-CBDD >10000 >10000 Hanus et al., 2005 15-LOX Atherosclerosis,
body weight
regulation
Takeda et al., 2009,
2011, 2015
(+)-CBDD >10000 >10000 Hanus et al., 2005 − −
(−)-DMH-CBDD >10000 >10000 Hanus et al., 2005 − −
(+)-DMH-CBDD >10000 <10000 Hanus et al., 2005 − −
KLS-13019 − − Neuroprotection Kinney et al., 2016
HUF-101 − − − Anxiety;
depression,
psychosis;
convulsion
Breuer et al., 2016
CBD-aldehyde-diacetate − − − Convulsion Carlini et al., 1975
6-Oxo-CBD-diacetate − − − Convulsion Carlini et al., 1975
6-OH-CBD-triacetate − − − Convulsion Carlini et al., 1975
9-OH-CBD-triacetate − − − Convulsion Carlini et al., 1975
HU-331 NR NR Kogan et al., 2004 Topoisomerase
IIα; Caspases;
ROS; PARP
Cancer Kogan et al., 2004,
2007; Petronzi et al.,
2013; Regal et al.,
2014
CBD-Q (V) − − PPARγ Neuroprotection Appendino et al., 2015
CBD-Q (VIII) − − PPARγ Neuroprotection Appendino et al., 2015
Abn-CBD − − GPR55;
GPR18
Vasodilatation;
bacteria; diabetes;
colitis
Johns et al., 2007;
Ryberg et al., 2007;
Appendino et al., 2008;
Console-Bram et al.,
2014; Krohn et al.,
2016; McKillop et al.,
2016
O-1602 NR NR GPR55;
GPR18
Central nervous
system;
metabolism
Johns et al., 2007;
Romero-Zerbo et al.,
2011; Ashton, 2012;
Console-Bram et al.,
2014
CBG 897 ± 596 153 ± 42 Rosenthaler et al., 2014 α2-AR; TRP;
COX-1; COX-2;
5-HT1A
Bacteria; bowel
inflammation;
depression
Appendino et al., 2008;
Cascio et al., 2010;
El-Alfy et al., 2010; De
Petrocellis et al., 2011;
Ruhaak et al., 2011;
Borrelli et al., 2013;
Rosenthaler et al., 2014
Cannabimovone >10000 >10000 Taglialatela-Scafati
et al., 2010
TPRV1 − Taglialatela-Scafati
et al., 2010
NR, no response.
Ferruginene C, a methylpentanol derivative of CBD
(Figure 5), was recently isolated from the leaves of Rhododendron
ferrugineum L. as a mixture of diastereoisomers (Seephonkai
et al., 2011). Ferruginene C has been shown to be cytotoxic in the
HL-60 cancer cell-line (IC50 13.7 µM) with selectivity toward
non-cancerous cell-line. It binds weakly to CB2 and TPRV1
receptors, but it did not show significant affinity for CB1 and
5-HT1A receptors (Table 1).
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FIGURE 3 | Aromatic analogs of CBD.
Even though linderatin (Figure 5), isolated from fresh leaves of
Lindera umbellata Thunb. (Tanaka et al., 1984), is not considered
a phytocannabinoid (Hanuš et al., 2016), it is interesting to
include in the present review since closely related to CBD. No
biological data have been reported so far.
SYNTHETIC CBD ANALOGS
Due to the promising therapeutic effects of CBD in a wide variety
of diseases, synthetic CBD derivatives have attracted the attention
of drug discovery programs in both industry and academia with
the aim to improve the potency, efficacy, or pharmacokinetic
properties of this interesting phytocannabinoid.
Synthetic approaches for different CBD metabolites such as
7-COOH-CBD or 7-OH-CBD (Figure 4) have been reported
(Tchilibon and Mechoulam, 2000; Mechoulam and Hanuš, 2002).
Moreover, structural modifications on different pharmacophoric
positions such as the lipophilic side chain, the phenolic hydroxyl
groups or the C7-methyl have been widely accomplished. In
addition to the (−)-CBD enantiomers, the (+)-CBD derivatives
[(+)-CBD depicted in Figure 6] have also been synthesized
and pharmacologically evaluated (Bisogno et al., 2001; Fride
et al., 2004; Hanus et al., 2005). Measurements of the binding
affinities of these compounds for the CB1 and CB2 cannabinoid
receptors yielded unexpected outcomes. Contrary to the naturally
occurring (−)-CBD analogs, which showed no orthosteric
affinity, most of the compounds in the (+)-CBD series bind to
both receptors displaying selectivity toward CB1 (Table 1).
Hydrogenation of CBD yielded the dihydro- and tetrahydro-
cannabidiol derivatives H2-CBD and H4-CBD (Figure 6) (Ben-
Shabat et al., 2006). Their effects on the production of reactive
oxygen intermediates, nitric oxide, and tumor necrosis factor
showed their anti-inflammatory capacity. In contrast to CBD,
H2-CBD, and H4-CBD have affinity for the cannabinoid CB1
receptor (Table 1). Additionally, the (−)- and (+)-dihydro-7-
hydroxy-CBD enantiomers (HU-446 and HU-465, Figure 6)
have recently been synthesized and biologically characterized in
an inflammatory model of encephalitogenic T cells (Kozela et al.,
2015). Both compounds showed anti-inflammatory potential
FIGURE 4 | Selected metabolites of CBD.
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in inflammatory and autoimmune diseases models. However,
only the (+)-enantiomer (HU-465) displays affinity for the
cannabinoid CB1 and CB2 receptors (Table 1).
1′,1′ -Dimethylheptyl-CBD Derivatives
Taking into account that substitution of the pentyl chain of
19–THC by a 1′, 1′-dimethylheptyl (DMH) lipophilic alkyl
chain resulted in more active compounds than natural 19–THC
(Mechoulam et al., 1988), a similar approach was performed for
the CBD scaffold (Mechoulam et al., 1990; Hanus et al., 2005)
(Table 1). Thus, the synthesis of DMH-CBD derivatives, such
as DMH-CBD, HU-320, DMH-CBDD, and 7-OH-DMH-CBD
(Figure 7) have been reported by Mechoulam and coworkers
(Leite et al., 1982; Hanus et al., 2005). Introduction of
the DMH alkyl chain in the (−)-DMH-CBD series did not
change the lack of CB1 and CB2 receptor affinity except for
(−)-7-OH-DMH-CBD that moderately binds to CB2 (Table 1)
(Bisogno et al., 2001). However, in the case of the (+)-DMH-CBD
series, the presence of the DMH alkyl chain improved
both CB1 receptor affinity compared to (+)-CBD (Table 1).
(−)-DMH-CBD analogs have displayed anxiolytic, analgesic,
anti-inflammatory, or antiproliferative effects in diverse assays
(Burstein, 2015). For instance, (−)-DMH-CBD has shown
anti-inflammatory and antiproliferative properties in human
acute myeloid leukemia, microglial or encephalitogenic T cells
(Juknat et al., 2016). The carboxylic acid HU-320 produced
strong anti-inflammatory and immunosuppressive effects in an
in vivo model of collagen-induced arthritis (Sumariwalla et al.,
2004). Interestingly, (−)-7-OH-DMH-CBD exhibited potent
inhibition of electrically evoked contractions of the mouse vas
deferens that was not mediated through CB1, CB2, TRPV1,
opioid, or α2-adrenergic receptors (Fride et al., 2005; Pertwee
et al., 2005).
As previously mentioned for the pentyl CBD derivatives,
hydrogenation of DMH-CBD has been studied (Ben-Shabat et al.,
2006). Partial hydrogenation gave H2-DMH-CBD (Figure 7) as
the major epimer (hydrogenation at C8) with small amounts of
the hydrogenated C1 epimer being obtained. Full hydrogenation
allowed the formation of H4-DMH-CBD (Figure 7). These
hydrogenated compounds, which bind to the CB1 receptor
with affinity constants in the nanomolar range, displayed
weak anti-inflammatory effects when compared to CBD or
DMH-CBD.
The pinene dimethoxy-DMH-CBD derivative HU-308
(Figure 7) was identified decades ago as a potent peripheral
CB2-selective agonist (Mechoulam et al., 1990; Hanus et al.,
1999). HU-308 has shown very interesting properties such as
anti-inflammatory, analgesic, neuroprotective or antitumor
effects, and has been used as a pharmacological tool in
numerous cannabinoid studies contributing to the progress
in this field (e.g., Hanus et al., 1999; Ofek et al., 2006; Rajesh
et al., 2007a,b; Burstein, 2015). More recently, the efficacy of
HU-308 and HU-433, two enantiomers, has been tested in
ovariectomy-induced bone loss and ear inflammation (Smoum
et al., 2015) showing an inverse relationship between binding
affinity and biological potency.
Other Modifications on the C4′-Alkyl
Chain
In order to improve oral bioavailability and solubility issues,
a novel series of CBD analogs have recently been synthesized
(Kinney et al., 2016) (Figure 8). Structural modifications
at the pharmacophoric lipophilic chain allowed fine-tuning
the “drug-likeness” of this scaffold by variation of different
physicochemical parameters such as the number of hydrogen
bond donors, acceptors, and polar surface area. Among these
new derivatives depicted in Figure 8, KLS-13019 stands
out as being 50-fold more potent and more than 400-fold
safer than CBD preventing damage to hippocampal neurons
induced by ammonium acetate and ethanol with improved oral
bioavailability compared to CBD (Kinney et al., 2016).
Halogenated CBD Derivatives
Structural modifications of CBD include halogenated
substituents on the phenol ring. The first reported halogenations
occurred at the 3′ and/or 5′ positions by chlorine, bromine or
iodine substitution, allowing the preparation of 3′-Cl-CBD,
3′,5′-diCl-CBD, 3′-Br-CBD, 3′,5′-diBr-CBD, 3′-I-CBD, and
3′,5′-diI-CBD (Figure 9) (Usami et al., 1999). These halogenated
compounds were evaluated in murine models of barbiturate-
induced sleep prolongation, electroshock-induced seizures and
locomotor activity resulting in activity similar to CBD for the
monohalogenated analogs, whereas the dihalogenated derivatives
displayed lower activity (Table 1).
The synthesis and pharmacological evaluation of three new
fluorine halogenated CBD derivatives have been reported (Breuer
et al., 2016). Two of these were fluorinated at the cyclohexenyl
ring substituent (Figure 10: HUF-102 and HUF-103), and
the third one was fluorinated at the phenol ring (HUF-101).
HUF-101 displayed the most promising results in four mice
behavioral assays (elevated plus-maze, forced swimming test,
prepulse inhibition, and marble burying test) that target
anxiolytic, antidepressant, antipsychotic and anticompulsive
activity respectively. HUF-101 may be an interesting prototype
for further development since it showed higher potency than
CBD in the animal assays cited above. In these tests, HUF-102
did not show activity at the doses tested (1–10 mg/kg),
whereas HUF-103 showed moderate to low activity compared to
HUF-101.
Modifications on the Hydroxyl Groups
Modifications on the resorcinol hydroxyl groups have been
explored. Computational studies suggested that the removal
of one of the CBD hydroxyl groups may enable the ligand
to reach the CB1 binding site (Reggio et al., 1995). Thus,
desoxy-CBD represented in Figure 11 was synthesized and
evaluated. Pharmacological data for desoxy-CBD corroborated
the computational studies showing CB1 partial agonism in the
mouse vas deferens assay.
Different research groups have developed acetylations and
alkylations at one or both phenolic hydroxyls. For instance, the
dimethylated CBD derivative named CBDD (Figure 11), as well
as the monomethylated derivative (CBD-2′-monomethylether o
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FIGURE 5 | Cannabidiol (CBD)-related Machaerium multiflorum, Rhododendron ferrugineum L. and, Lindera umbellata Thunb. compounds.
FIGURE 6 | (+)-CBD and hydrogenated CBD derivatives.
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FIGURE 7 | Dimethylheptyl (DMH)-CBD derivatives.
FIGURE 8 | Cannabidiol analogs modified on the C4′-alkyl chain.
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FIGURE 9 | Chlorinated, brominated, and iodinated CBD derivatives.
O-methylcannabidiol) revealed higher potency and selectivity
as 15-lipoxygenase inhibitors compared to CBD (Takeda et al.,
2009, 2011). Consequently, the resorcinol moiety seems to be
a determinant for the activity in this target. Further studies
performed with CBDD suggest that this compound is not
only a potential prototype for atherosclerosis treatment, but
also a pharmacological tool to study the mechanisms of body
weight regulation (Takeda et al., 2015). Other alkylations on
the phenolic hydroxyl group have been reported such as
O-propyl- and O-pentylcannabidiol that have been structurally
characterized but no pharmacological data have been described
so far (Hendricks et al., 1978).
Cannabidiol derivatives bearing one or both hydroxyl
substitutions have been reported in the patent literature to be
active as anti-inflammatory agents (Mechoulam et al., 2008).
Selected examples disclosed in this patent (HU-410, HU-427, and
HU-432) are depicted in Figure 11. It is interesting to highlight
that some of these compounds present improved solubility,
stability and bioavailability parameters when compared with
CBD. Likewise, the non-CB1, non-CB2 ligand HU-444 has shown
anti-inflammatory properties in vitro and in vivo in a murine
model of collagen-induced arthritis (Haj et al., 2015).
In addition, the in vivo anticonvulsant activity of
four diacetylated-CBD analogs (CBD-aldehyde-diacetate,
6-oxo-CBD-diacetate, 6-hydroxy-CBD-triacetate, and 9-
hydroxy-CBD-triacetate, Figure 12) was demonstrated in a
mouse model (Carlini et al., 1975). Their effects against maximal
electroshock convulsions, potentiation of pentobarbital sleeping-
time and reduction of spontaneous motor activity were evaluated
obtaining significant anticonvulsant effects at high doses. It
is noteworthy that the safety, efficiency, and potency of these
four compounds were lower than that of CBD in the same
assays.
At that point it is interesting to mention that these
diacetate CBD derivatives could have been considered as
prodrugs. Considering that CBD is rapidly distributed in adipose
tissues and it undergoes a CYP3A- and CYP2C- dependent
first-pass metabolism to give 7-hydroxy-CBD (Fasinu et al.,
2016), a prodrug concept could be very useful. Therefore,
the phenyl acetate groups could be deacetylated to give CBD.
The pharmaceutical company, AllTranz, now called Zyberba
Pharmaceutics, developed transdermal solutions of CBD-esters
and -carbonates among others. The dicarbonate All00102
and the diglicolate AL00147 shown in Figure 11 are two
examples disclosed in a AllTranz’s patent (Stinchcomb et al.,
2009). Another company, Kalytera Therapeutics is currently
undertaking the preclinical stage of K-1012, a bi-phosphate
derivative of CBD designed as a prodrug indicated for acute
respiratory distress syndrome.2
Quinone Derivatives of CBD
The quinone derivative of CBD, HU331, was first synthesized
in Mechoulam et al. (1968) by oxidation of CBD. HU331 has
been suggested to be a CBD metabolite having inhibitory effect
on cytochrome P450 (Bornheim and Grillo, 1998). It was not
until Kogan et al. (2004) that the antineoplastic activity of
HU-331 was reported. HU-331 was very effective in reducing
growth of human colon carcinoma HT-29 cells in nude mice.
The mechanism by which HU-331 acts as an antitumor agent is
independent of the CB1 and CB2 cannabinoid receptors. HU-331
does not promote cell death via cell cycle arrest, cell apoptosis,
or caspase activation. Extensive studies have shown that HU-331
anticancer properties were due to selective inhibition of the
ATPase function of human topoisomerase IIα (Kogan et al.,
2https://kalytera.co/programs/preclinical/ (accessed June 8, 2017).
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FIGURE 10 | Fluorinated CBD derivatives.
FIGURE 11 | Cannabidiol derivatives modified at the hydroxyl groups.
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FIGURE 12 | Diacetylated-CBD analogs.
FIGURE 13 | Quinones related to CBD.
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FIGURE 14 | Miscellaneous CBD derivatives.
2007; Peters and Kogan, 2007; Regal et al., 2014). Thus, HU-331
with a selective topoisomerase inhibition is expected to have
less off-target toxicity than doxorubicin which antitumor activity
is mediated through numerous mechanisms, such as apoptosis,
abrogation of the cell cycle, activation of caspases, generation of
ROS, and inhibition of both topoisomerases among others.
Structural modifications realized on the substituents of
HU-331 led to the benzoquinones having anti-proliferative
activity against diverse cancer cell lines (Petronzi et al., 2013).
Unlike HU-331, benzoquinone mechanism of action involves
caspase activation, poly-(ADP-ribose)-polymerase (PARP)
protein cleavage, and reactive oxygen species (ROS) production.
These data show the influence of CBD structure compared to the
quinone core on the processes producing anticancer effects.
A recent patent from VivaCell Technology discloses HU-331
analogs which act as PPARγ agonists showing a neuroprotective
profile in different models (Appendino et al., 2015). The disclosed
quinones are substituted in position 3′ by different amines or
carboxylates that were synthesized by amination of CBD or
esterification of CBDA respectively. Compounds CBD-Q (V) and
CBD-Q (VIII) illustrated in Figure 13 are representative of the
HU-331 analogs.
Miscellaneous CBD Derivatives
Abnormal cannabidiol (Abn-CBD) (Razdan et al., 1974), a
non-psychoactive synthetic regioisomer of CBD (Figure 14), has
been the subject of numerous studies that have shown Abn-CBD
therapeutic potential as a vasodilator (Johns et al., 2007),
antibacterial (Appendino et al., 2008), antidiabetic (McKillop
et al., 2016), or anti-colitis agent (Krohn et al., 2016). Recently,
two molecular targets, GPR55 and GPR18, have been identified
for Abn-CBD (Johns et al., 2007; Ryberg et al., 2007; Console-
Bram et al., 2014). Abn-CBD stimulated [35S]GTPγS binding at
GPR55 (Oka et al., 2007) and increased calcium mobilization and
ERK1/2 phosphorylation at GPR18 (Console-Bram et al., 2014).
The synthetic cannabinoid O-1602 that does not bind
significantly to CB1 or CB2 receptors, stimulates GTPγS
activation in membranes from human recombinant
GPR55-expressing cells (EC50 = 1.4 nM) (Johns et al.,
2007; Console-Bram et al., 2014). In vivo, O-1602 showed
anti-inflammatory activity in mice with cerulein-induced acute
pancreatitis characterized by an increased expression of GPR55
receptor (Li et al., 2013). O-1602 has also been shown to
increase levels of GPR18-mediated MAPK activity and calcium
mobilization, but not β-arrestin signaling, thus supporting
that O-1602 acts as a biased-agonist at GPR18 (Console-Bram
et al., 2014). Data have been reported suggesting the therapeutic
potential of O-1602 for diseases related to the central nervous
system (Ashton, 2012), or to metabolic diseases (Romero-Zerbo
et al., 2011).
Another minor component of Cannabis sativa is cannabigerol
(CBG) (Gaoni and Mechoulam, 1971). Structurally, CBG
can be considered the cyclohexenyl-opened analog of CBD.
Different therapeutic applications have been proposed for CBG,
more recently CBG has been shown to have antibacterial
action (Appendino et al., 2008), antidepressant-like action
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(El-Alfy et al., 2010), and anti-inflammatory properties for bowel
disease (Borrelli et al., 2013). Molecular targets of CBG include
the α2 adrenergic receptor, TRP channels, cyclooxygenase (COX-
1 and COX-2) enzymes, as well as the 5-HT1A and cannabinoid
receptors (Cascio et al., 2010; De Petrocellis et al., 2011; Ruhaak
et al., 2011). Cannabimovone is one of the latest natural
phytocannabinoids that has been extracted from a cultivar of
hemp rich in CBD (Taglialatela-Scafati et al., 2010). The terpenoid
structure of cannabimovone replaces the cyclohexenyl ring of
CBD by a functionalized cyclopentane including four contiguous
stereocenters. Its total synthesis has been reported very recently
(Carreras et al., 2016). Cannabimovone is devoid of CB1 and CB2
activity, whereas it is a weak TPRV1 agonist.
CONCLUSION
A significant amount of preclinical data has shown the
high therapeutic potential of CBD especially in inflammatory
mouse models. According to ClinicalTrials.gov records, CBD
is currently tested in clinical phases for different inflammatory
diseases. The results of the first clinical study of CDB for the
treatment of inflammatory bowel have been published very
recently. Unfortunately, the effects of CBD on Crohn’s disease
were ineffective in a randomized placebo-controlled trial on
20 patients probably due to low used doses (Naftali et al.,
2017). The potential antiepileptic effects of CBD in patients
suffering seizures associated with Lennox–Gastaut syndrome
and in children and young patients with Dravet syndrome are
currently on-going. The research has tended to focus on CBD
therapeutic applications. Less attention has been paid to the
therapeutic utility of CBD derivatives.
Despite the identifications of CBD metabolites and naturally
occurring CBD analogs, in general, their pharmacological
properties have not been extensively studies. In what concerns
synthetic CBD-based compounds, several of them have shown
interesting pharmacological properties but none has been
introduced into clinical trials yet. In a pharmacological point of
view, whereas CBD does not have affinity for both classical CB1
and CB2 cannabinoid receptors, most of (+)-CBD derivatives do
bind to CB1 and/or CB2 receptors. Others, such as Abn-CBD,
O-1602, CBG, cannabimovone, ferruginene C, (−)-CBDV, and
(−)-CBDA, have shown activity at other receptors including
TPRV1, GPR35 and/or GPR18 receptors, or enzymes such as
COX-2. A limitation of the development of CBD synthetic
derivatives probably resides in the lack of a unique common
molecular target.
In future therapeutic development of CBD derivatives,
it will be prudent to take into account some structural
considerations around the CBD scaffold. One of them is
the possible atropisomerism around the phenyl–hexenyl bond.
Ortho-substitution on the phenyl ring could have stereochemical
consequences generating hindered rotation of the phenyl–
hexenyl bond due to steric or electronic constraints, generating
two isolable conformers in the case of slow interconversion
(Berber et al., 2014; Flos et al., 2016). Thus, it is necessary to
consider the implication of a possible atropoisomerism for new
CBD analogs discovery (Clayden et al., 2009).
The complexity of the pharmacological processes of CBD
and CBD analogs suggest that a better understanding of their
mechanism of action is required to devise successful synthetic
CBD-based drug therapies.
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